Trade name : Taffic
Active ingredient : Tenofovir Alafenamide + Emtricitabine + Bictegravir
Strength availability : 25mg + 200mg + 50mg
Manufactured by : Hetero
Package : 30 Tablets
Taffic is an anti-retroviral drug containing three prominent factors is known as; Tenofovir Alafenamide Emtricitabine Bictegravir Tenofovir Alafenamide is a nucleotide transcriptase inhibitor Emtricitabine is a nucleoside reverse transcriptase inhibitor Bictegravir is an integrase inhibitor.
These are the most effective & a potent compound against HIV-1 infections, but it does not cure the infection situation it is only used for preventing & suppressing the evolution of HIV-1 infection into AIDS. In Taffic tablets, TAF is present as a prodrug. Emtricitabine is synthetics fluoro derivative of thiacytodone. Bictegravir is an investigational drug.
Taffic is a combination tablet contains Tenofovir Alafenamide, Emtricitabine & Bictegravir is mainly indicated for the treatment of HIV-1 infection in adult’s patients.
The prescribed dose of Taffic is one tablet that should be given orally as day-to-day. Important points; before starting the treatment, the patient should be considered for the presence of hepatitis B infection or not.
The patient’s renal values should be investigated for the creatinine approval, urine glucose & urine protein. Taffic should be used in adolescents, a pediatric patient with weighing at least 25kg & creatinine clearance of patients should be larger or equal to 30ml/min.
Taffic should not be suitable for patients with creatinine clearance below 30ml/min. Taffic tablets should be executed with food or without food.
Taffic is a nucleoside reverse transcriptase inhibitor (carboxylic synthetic nucleoside analog),
it has activity against human immunodeficiency virus type I.
Taffic is phosphorylated into an active metabolite carbovir triphosphate (deoxyguanosine 5’triphosphate) dGTP.This active metabolite forbid the action of reverse transcriptase by spar with dGTP and inserted into viral DNA.
The growth of viral DNA gets concerned by the infusion of nucleotide which causes lack of OH molecule. OH, molecules are vital for the formation of 5’ to 3’ phosphodiester linkage which is guilty of chain extension.
The annoyance of HIV-1 infection: Patients should be considered earlier for the development of HIV infection or not.
The influence of Taffic tablets for growing HIV-1 infection has not been assessing. These circumstances mostly occurred in patients
who are HIV-1 co-infected.
Immune reconstitution syndrome: To overcome the problem by interrupting the treatment with Taffic. Renal deterioration worsening: Stop using Taffic with drugs affecting the renal functions. Monitor the creatinine clearance value frequently. In severe conditions, CrCl below 30ml/min use of Taffic should be avoided. Lactic acidosis & hepatic steatosis: Terminate the therapy using Taffic.
Taffic + P-GP or BCRP potent inhibitors: affect the consumption of TAF. Taffic + potent P-GP or BCRP inducers: decrease the consumption of TAF causes reducing=g the plasma concentration of TAF and certainly results as loss of effectiveness of Taffic. Taffic removal process occurs through kidneys; a combination of Taffic with drugs affecting the renal activity causes increasing the effect of concentration of ingredients of Taffic & concludes as achieve of adverse effects associated with these components.
Taffic combines with drugs like Tipranavir/Ritonavir causes diminishing the effect of the concentration of TAF. Taffic concurrently used with anti-convulsions causes decreasing the effect of concentration of TAF. Taffic concurrently used with anti-mycobacterium or st Johns wort causes decreasing the effect of concentration of TAF. Inhibition of both CYP3A4 and UGT1A1 by a co-administered drug could potentially lead to significant increases in BIC exposure, while potent induction of these enzymes may significantly reduce BIC exposure.
Taffic has differed to patients with CrCl below 30ml/min Anaphylactic reactions are formed due to patients are contraindicated to the factor of Taffic.
The overdosage of Taffic should be considered with hemodialysis. Emtricitabine should be evacuated by a 30% range after completing 3 hours of dialysis method. TAF should be removed by 54% of range after 4 hours dialysis session. Bictegravir is highly obligated to plasma proteins; it is strange that it will be necessarily removed by hemodialysis or peritoneal dialysis.
Common side effects:
• Abnormal dreams
• Feeling sick (nausea)
• Tiredness (fatigue)
Uncommon side effects:
• Stomach pain
• Difficulty with digestion resulting in discomfort after meals (dyspepsia)
• wind (flatulence)
• swelling of the face, lips, tongue or throat (angioedema)
• itching (pruritus)
• Joint pain (arthralgia)
• Suicidal behavior
• sleep disorders
The efficiency & influence of Taffic should not be calculated in pediatric patients with weighing below 25kg.
The efficiency of Taffic should not be estimated in clinical trials for geriatric patients at the age of above 65 years.
The uses of Taffic should be prevented in patients with CrCl below 30ml/min.